[Outcome of Cytoreductive Surgery(CRS)+Hyperthermic Intraperitoneal Chemotherapy(HIPEC)for Appendiceal Pseudomyxoma Peritonei].

Abstract

Pseudomyxoma peritonei(PMP)is rare disease, but in other countries, cytoreductive surgery(CRS)plus hyperthermic intraperitoneal chemotherapy(HIPEC)is the standard treatment, but in Japan it is not covered by insurance and is only being treated at a few institutions. In 2021, Japanese Society of Peritoneal Malignancy issued Clinical Practice Guideline for Peritoneal Malignancy, in which CRS+HIPEC was weakly recommended, but few new centres have started this treatment as it is not covered by insurance. We have been performing CRS+HIPEC for PMP and peritoneal dissemination of colorectal cancer since 1990, and hope to expand this treatment by reporting on our methods and outcomes.